Emerging and Innovative Theranostic Approaches for Mesoporous Silica Nanoparticles in Hepatocellular Carcinoma: Current Status and Advances

Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal solid cancers globally. To improve diagnosis sensitivities and treatment efficacies, the development of new theranostic nanoplatforms for efficient HCC management is urgently needed. In the past decade, mesoporous silica nanoparticles (MSNs) with tailored structure, large surface area, high agents loading volume, abundant chemistry functionality, acceptable biocompatibility have received more and more attention in HCC theranostic. This review outlines the recent advances in MSNs-based systems for HCC therapy and diagnosis. The multifunctional hybrid nanostructures that have both of therapy and diagnosis abilities are highlighted. And the precision delivery strategies of MSNs in HCC are also discussed. Final, we conclude with our personal perspectives on the future development and challenges of MSNs.

Delivery of microRNA-33 Antagomirs by Mesoporous Silica Nanoparticles to Ameliorate Lipid Metabolic Disorders

“…Moreover, nanocarriers are promising carriers for gene delivery (Canup et al, 2017;Wang et al, 2018;Zai et al, 2019). Among the various types of nanoparticles (NPs) being used, mesoporous silica nanoparticles (MSNs) are promising vectors, owing to their unique characteristics of a tailored structure, large surface area, high agent-loading volume, abundant chemistry functionality, and acceptable biocompatibility (Tang et al, 2012;Zhou et al, 2018;Tao et al, 2020). Owing to these distinctive features, MSNs can serve as multifunctional and efficient platforms for gene delivery (Keasberry et al, 2017;Lin et al, 2018).…”

Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic

“…In addition, easy surface modification of MSNs can promote the development of active targeting and tumor-specific, drug-release nanoagents against HCC. Scientists have summarized the advantages of MSNs as drug carriers against HCC (including therapeutic and diagnostic agents) (Tao et al, 2020). However, the attractiveness of silica-based nanomaterials is not limited to the field of drug delivery (Kumar et al, 2018;Živojević et al, 2021).…”

“…Furthermore, MSNs can overcome MDR by co-delivering antitumor agents, thus providing a new approach to cancer therapy ( Xue et al, 2017 ; Wu et al, 2018 ). Up to now, several reviews have summarized and analyzed the nano drug-delivery systems (nDDS) developed based on MSNs, fully demonstrating the potentials of this material in oncology diagnosis and treatment ( Tao et al, 2020 ; Gao et al, 2020 ; Mohamed Isa et al, 2021 ). However, most of these reviews summarized MSNs as multi-functional drug carriers ( Paris and Vallet-Regí, 2020 ; Mohamed Isa et al, 2021 ) or stimuli-responsive delivery platforms ( Li et al, 2019a ; Barui and Cauda, 2020 ; Živojević et al, 2021 ) for the treatment of tumors and other diseases such as osteosarcoma ( Quadros et al, 2021 ), breast cancer ( Poonia et al, 2018 ), glioblastoma ( Nam et al, 2018 ), prostate cancer ( Farina et al, 2018 ), atherosclerosis ( Sha et al, 2021 ) and rheumatoid arthritis ( Madav et al, 2020 ).…”

Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma

“…Nanotheranostic is a real-time combination of novel therapeutic and modern diagnostic tool or imaging into a single agent linked and integrated by nanoparticles[ 39 , 40 ]. Nanoparticles are the key components of the nanotheranostic agent[ 41 ] which include aptamer[ 42 ], DNA nanostructure[ 43 ], lactosome-based nanoparticles[ 44 ], metallic nanoparticles[ 45 ], gold nanoparticle[ 46 ], silver nanoparticle[ 47 ], dendrimer and copolymer-based nanoparticles[ 48 ], lipid-based nanomaterials[ 49 ], magnetic nanoparticles[ 50 ] iron oxide nanoparticle[ 51 ], mesoporous silica nanoparticle[ 52 ] and quantum dots nanoparticle[ 53 ].…”